IL10 and cancer: Meanwhile, the destroyed bacteria and cancer cells can activate immune cells (such as macrophages, neutrophils, and dendritic cells), which release inflammatory cytokines (TNF-α and IL-1β) and reduce anti-inflammatory cytokines (IL-10), thereby further enhancing the efficacy of cancer immunotherapy.